Track topics on Twitter Track topics that are important to you
Cancer Research UK and Biotecnol said they will advance an immuno-oncology treatment for lung cancers and other solid tumors into early phase clinical trials, through a collaboration whose value was not disclosed. Cancer Research UK will support early clinical development of Biotecnol’s first-in-class drug Tb535H. The anti-5T4 pan-cancer T-cell engager is designed to work by recruiting the patient’s T-cells and directing them to attack tumors by targeting the 5T4/WAIF1 tumor antigen, a protein thought to contribute to the spread of cancer cells, and found on numerous solid tumors. Biotecnol and Cancer Research UK’s Centre for Drug Development will partner to advance Tb535H through a Biotecnol-sponsored first-in-humans Phase I clinical trial, using Cancer Research UK’s drug development expertise in return for a stake in Biotecnol. The WAIF1 antigen was discovered by researchers at the Cancer Research UK Manchester Institute. While it could prove a valuable target against ...NEXT ARTICLE
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...
Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...
Pulmonary relating to or associated with the lungs eg Asthma, chronic bronchitis, emphysema, COPD, Cystic Fibrosis, Influenza, Lung Cancer, Pneumonia, Pulmonary Arterial Hypertension, Sleep Disorders etc Follow and track Lung Cancer News ...